HOME >> BIOLOGY >> NEWS
JCI Table of Contents, May 1, 2003

: 513-636-3557
Fax : 513-636-5958
E-mail: MolkJ0@CHMCC.org

View the PDF of this commentary at: https://www.the-jci.org/press/18389.pdf


A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptordeficient mice

AUTHOR CONTACT:
Roland Baron
Yale University School of Medicine, New Haven, Connecticut, USA.
Phone: 203-785-4150
Fax: 203-785-2744
E-mail: roland.baron@yale.edu

View the PDF of this article at: https://www.the-jci.org/press/17246.pdf


Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

AUTHOR CONTACT:
Roland W. Herzog
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Phone: 215-590-4907
Fax: 215-590-3660
E-mail: rwherzog@mail.med.upenn.edu

View the PDF of this article at: https://www.the-jci.org/press/16887.pdf


The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance

AUTHOR CONTACT:
Ronald Khan
Joslin Diabetes Center, Boston, Massachusetts, USA.
Phone: 617-732-2635
Fax: 617-732-2593
E-mail: Ron.Kahn@joslin.harvard.edu

View the PDF of this article at: https://www.the-jci.org/press/15211.pdf


The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, 15 August 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI Table Contents May

(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
Cached News: